Stockscreener 앱 받기
562.16
0.46%
-2.58
시간 외 거래:
562.16
전일 마감가:
$564.74
열려 있는:
$567.07
하루 거래량:
459.09K
Relative Volume:
0.79
시가총액:
$44.34B
수익:
$4.45B
순이익/손실:
$1.10B
주가수익비율:
41.36
EPS:
13.591
순현금흐름:
$1.06B
1주 성능:
-0.24%
1개월 성능:
-0.14%
6개월 성능:
-21.28%
1년 성능:
+7.65%
1일 변동 폭
$560.38
$569.06
1주일 범위
$547.57
$577.49
52주 변동 폭
$506.91
$769.98
아이덱스 래버러토리스 Stock (IDXX) Company Profile
명칭
Idexx Laboratories Inc
전화
(207) 556-0300
주소
ONE IDEXX DRIVE, WESTBROOK, ME
Compare IDXX vs TMO, DHR, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
아이덱스 래버러토리스 Stock (IDXX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-15 | 개시 | Citigroup | Neutral |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-31 | 업그레이드 | Stifel | Hold → Buy |
| 2025-10-01 | 개시 | UBS | Neutral |
| 2025-08-05 | 재확인 | BTIG Research | Buy |
| 2025-07-01 | 개시 | Jefferies | Buy |
| 2024-12-02 | 개시 | Leerink Partners | Outperform |
| 2024-07-25 | 개시 | BTIG Research | Buy |
| 2024-01-30 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-12-07 | 개시 | Exane BNP Paribas | Outperform |
| 2023-12-04 | 업그레이드 | Cleveland Research | Neutral → Buy |
| 2023-08-02 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-07-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-07-21 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-07-12 | 개시 | Piper Sandler | Overweight |
| 2022-05-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-02-08 | 개시 | Atlantic Equities | Overweight |
| 2021-11-18 | 개시 | Morgan Stanley | Overweight |
| 2021-08-05 | 재개 | Credit Suisse | Outperform |
| 2021-07-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-17 | 개시 | Barclays | Overweight |
| 2019-09-09 | 개시 | Goldman | Neutral |
| 2019-05-23 | 개시 | Guggenheim | Buy |
| 2018-11-02 | 재확인 | BofA/Merrill | Buy |
| 2018-05-07 | 재확인 | Stifel | Buy |
| 2018-01-16 | 개시 | Piper Jaffray | Overweight |
| 2017-08-23 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2017-07-28 | 업그레이드 | CL King | Neutral → Buy |
| 2017-02-03 | 다운그레이드 | Feltl & Co. | Hold → Sell |
| 2016-09-29 | 재개 | BofA/Merrill | Neutral |
| 2016-08-16 | 재확인 | Stifel | Buy |
| 2016-08-03 | 업그레이드 | Northcoast | Sell → Neutral |
| 2016-07-20 | 재확인 | Canaccord Genuity | Buy |
| 2016-04-19 | 재확인 | Canaccord Genuity | Buy |
| 2016-04-01 | 개시 | CL King | Neutral |
| 2016-03-21 | 재확인 | Stifel | Buy |
| 2016-02-04 | 개시 | Credit Suisse | Outperform |
| 2015-10-29 | 재확인 | Stifel | Buy |
| 2015-08-28 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2015-08-13 | 재확인 | Stifel | Buy |
| 2015-07-23 | 재확인 | Canaccord Genuity | Buy |
모두보기
아이덱스 래버러토리스 주식(IDXX)의 최신 뉴스
IDEXX Laboratories touts AI push, inVue Dx momentum at Stifel conference - MSN
Is Wall Street bullish or bearish on IDEXX Laboratories stock? - MSN
IDEXX Parasite Test Expansion Links Zoonotic Risk And Valuation Debate - Yahoo Finance
IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch
IDEXX (IDXX) EVP Fennell reports RSU vesting and tax share withholding - Stock Titan
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: Unveiling 25.84% Potential Upside in the Diagnostics Market - DirectorsTalk Interviews
How Investors May Respond To IDEXX (IDXX) Expanding SDMA and Fecal Dx Integration in Diagnostics - Sahm
IDEXX Laboratories Inc stock (US45167R1041): shares steady as investors digest AI strategy and secto - AD HOC NEWS
IDEXX Laboratories Touts AI Push, inVue Dx Momentum at Stifel Conference - Yahoo Finance
A Look at IDEXX Laboratories Inc (IDXX) After 3.1% Gain -- GF Va - GuruFocus
IDEXX Laboratories (IDXX) Embeds an Early Kidney Disease Detector Into Its Most Popular Test Profile - Insider Monkey
IDEXX Laboratories stock (US45168D1046): solid Q1 update keeps animal health growth story in focus - AD HOC NEWS
IDEXX Laboratories Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
IDEXX Laboratories Expands Fecal Antigen Testing Platform With Tapeworm Detection - Moomoo
IDEXX Laboratories Inc at Stifel Jaws & Paws Conference Transcript - GuruFocus
IDEXX expands fecal testing to detect taeniid tapeworms By Investing.com - Investing.com Nigeria
Is Wall Street Bullish or Bearish on IDEXX Laboratories Stock? - Barchart.com
IDEXX expands fecal testing to detect taeniid tapeworms - Investing.com
IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection - Business Wire
IDEXX Expands Fecal Dx Antigen Testing Platform with Taeniid Tapeworm Detection – Company Announcement - Financial Times
11 Best Medical Technology Stocks to Buy Right Now - Insider Monkey
IDEXX Laboratories stock (US45168D1046): strong Q1 earnings keep diagnostics specialist in focus - AD HOC NEWS
IDEXX Laboratories, Inc. (IDXX) Investor Outlook: Unveiling a 26.78% Potential Upside in the Diagnostics Arena - DirectorsTalk Interviews
IDEXX Laboratories (IDXX) Is Up 5.8% After Embedding SDMA Into Routine Catalyst CLIPs Testing - Sahm
IDEXX Laboratories stock (US45168D1046): institutional selldown and animal health growth story - AD HOC NEWS
Insider sale notice: IDEXX Labs (NASDAQ: IDXX) files Form 144 - Stock Titan
HARVEY INVESTMENT CO LLC's IDEXX Laboratories Inc(IDXX) Holding History - GuruFocus
Should IDEXX’s (IDXX) SDMA-Enhanced Catalyst Panels Prompt Action From Long-Term Diagnostics Investors? - Yahoo Finance
IDEXX announces UK availability of cancer Dx panel for early detection of canine lymphoma - MSN
IDEXX Laboratories stock (US45168D1046): Q1 2026 earnings beat, guidance hike and new kidney test in - AD HOC NEWS
IDEXX Laboratories stock (US45168D1046): Q1 2026 earnings beat and updated guidance keep veterinary - AD HOC NEWS
IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles - Business Wire
IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles – Company Announcement - Financial Times
IDEXX Laboratories Inc (IDXX) Stock Up 3.2% and Still Undervalued -- GF Score: 99/100 - GuruFocus
IDEXX Laboratories stock (US45168D1046): fresh Q1 2026 earnings and guidance put diagnostics special - AD HOC NEWS
IDEXX Laboratories, Inc. (IDXX) Stock Analysis: Exploring a 34% Potential Upside for Investors - DirectorsTalk Interviews
Elyxium Wealth LLC Invests $3.67 Billion in IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories, Inc. $IDXX Shares Sold by Thrivent Financial for Lutherans - MarketBeat
Idexx Laboratories Shareholders Approve Governance and Meeting Reforms - The Globe and Mail
IDEXX Laboratories stock (US45167R1041): Diagnostics demand keeps investors focused - AD HOC NEWS
IDXX Technical Analysis & Stock Price Forecast - Intellectia AI
Northwestern Mutual Wealth Management Co. Increases Position in IDEXX Laboratories, Inc. $IDXX - MarketBeat
IDEXX Laboratories stock (US45168D1046): Q1 2025 earnings highlight growth in pet diagnostics - AD HOC NEWS
IDEXX (NASDAQ: IDXX) declassifies board, grants 25% special-meeting right - Stock Titan
아이덱스 래버러토리스 (IDXX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.12%
자본화:
|
볼륨(24시간):